New antibody takes on Hard-to-Treat cancers
Disease control
Ongoing
This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC